NEW YORK (GenomeWeb News) – Bruker reported today that its revenues in the third quarter were down 2 percent year over year, falling to $439 million from $447.8 million in Q3 2012.

The drop was driven by weakness in the company's Energy and Semiconducting Technologies (BEST) segment, which saw revenue decline by 27 percent in the quarter. Bruker's Scientific Instruments segment, which includes its mass spectrometry and life sciences business, grew a fraction of 1 percent year over year.

The results fell short of the average Wall Street estimate of $452.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.